Forazemin: Precision antibiotic for periodontal pathobionts
Forazemin is a precision antibiotic targeting periodontal pathobionts, offering a selective alternative to broad-spectrum treatments. It eliminates harmful bacteria, reduces inflammation, and promotes tissue regeneration while preserving beneficial oral microbiota.
Overview
Forazemin is an innovative precision antibiotic designed to address periodontal disease, a condition affecting over a billion people worldwide. Unlike traditional broad-spectrum antibiotics, Forazemin selectively targets Gram-negative anaerobic bacteria responsible for periodontal disease, while sparing beneficial commensal bacteria essential for oral health. This targeted approach not only effectively eliminates harmful pathogens but also reduces inflammation and promotes the regeneration of tissue and bone, offering a restorative treatment alternative.
Technical specifications
Key features:
- Selectively targets Gram-negative anaerobic pathobionts responsible for periodontal disease
- Demonstrated efficacy in in vitro antimicrobial tests and rat ligature-induced periodontitis model
- Reduces inflammation and supports regeneration of connective tissue and alveolar bone
- Preserves beneficial oral microbiota, minimizing disruption to overall oral health
Technology readiness level
Forazemin is at Technology Readiness Level 6, indicating that it has been validated in relevant environments, including in vitro and animal models. Further development will involve more in vivo models and clinical trials to confirm its efficacy and safety in human populations.
About Northeastern University
Northeastern University is a private, comprehensive R1 research university based in Boston with a global campus network. Its century-old cooperative education model integrates full-time, paid placements with academic study, enabling companies to access vetted talent and long-term pipelines worldwide. Industry collaboration is supported by a suburban innovation campus offering test beds, secure labs, and fee-for-use core facilities, alongside co-located partner spaces. The university attracts competitive federal research funding from agencies such as the NSF and NIH. A dedicated technology transfer office streamlines IP, licensing, and startup formation for corporate partnerships.
delivered to your inbox.